JP2020530437A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530437A5 JP2020530437A5 JP2019570982A JP2019570982A JP2020530437A5 JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5 JP 2019570982 A JP2019570982 A JP 2019570982A JP 2019570982 A JP2019570982 A JP 2019570982A JP 2020530437 A5 JP2020530437 A5 JP 2020530437A5
- Authority
- JP
- Japan
- Prior art keywords
- tumor
- neopeptides
- fusion
- recombinant poxvirus
- cancer vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023100296A JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305760.5 | 2017-06-21 | ||
| EP17305760 | 2017-06-21 | ||
| EP18305496 | 2018-04-23 | ||
| EP18305496.4 | 2018-04-23 | ||
| PCT/EP2018/066668 WO2018234506A2 (en) | 2017-06-21 | 2018-06-21 | PERSONALIZED VACCINE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Division JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2020530437A JP2020530437A (ja) | 2020-10-22 |
| JP2020530437A5 true JP2020530437A5 (enExample) | 2021-09-24 |
| JPWO2018234506A5 JPWO2018234506A5 (enExample) | 2023-07-05 |
| JP7334124B2 JP7334124B2 (ja) | 2023-08-28 |
Family
ID=62599637
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019570982A Active JP7334124B2 (ja) | 2017-06-21 | 2018-06-21 | 個別化ワクチン |
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023100296A Pending JP2023123609A (ja) | 2017-06-21 | 2023-06-19 | 個別化ワクチン |
| JP2025121773A Pending JP2025160281A (ja) | 2017-06-21 | 2025-07-18 | 個別化ワクチン |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US11969462B2 (enExample) |
| EP (1) | EP3641803A2 (enExample) |
| JP (3) | JP7334124B2 (enExample) |
| KR (2) | KR102684237B1 (enExample) |
| CN (1) | CN111065406A (enExample) |
| AU (1) | AU2018287159B2 (enExample) |
| CA (1) | CA3067405A1 (enExample) |
| IL (1) | IL271558B2 (enExample) |
| SG (1) | SG11201912429RA (enExample) |
| WO (1) | WO2018234506A2 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3826669A2 (en) | 2018-07-26 | 2021-06-02 | Frame Pharmaceuticals B.V. | Off-the-shelf cancer vaccines |
| CA3124905A1 (en) * | 2019-01-03 | 2020-07-09 | Jens KRINGELUM | Vaccines targeting neoepitopes |
| TWI852977B (zh) | 2019-01-10 | 2024-08-21 | 美商健生生物科技公司 | 前列腺新抗原及其用途 |
| CN113631185A (zh) * | 2019-02-27 | 2021-11-09 | 尼克塔治疗公司 | 用于治疗癌症的免疫治疗组合 |
| US20220290179A1 (en) * | 2019-08-29 | 2022-09-15 | Astellas Pharma Inc. | Genetically engineered oncolytic vaccinia viruses and methods of uses thereof |
| AU2020385683A1 (en) | 2019-11-18 | 2022-06-30 | Janssen Biotech, Inc. | Vaccines based on mutant CALR and JAK2 and their uses |
| EP3842065A1 (en) * | 2019-12-23 | 2021-06-30 | Transgene | Process for designing a recombinant poxvirus for a therapeutic vaccine |
| US20230097513A1 (en) * | 2020-02-03 | 2023-03-30 | City Of Hope | Poxvirus-based vectors produced by natural or synthetic dna and uses thereof |
| CN111303277A (zh) * | 2020-02-19 | 2020-06-19 | 中国人民解放军军事科学院军事医学研究院 | 一种抗天花病毒免疫球蛋白F(ab′)2及其制备方法 |
| WO2022009052A2 (en) | 2020-07-06 | 2022-01-13 | Janssen Biotech, Inc. | Prostate neoantigens and their uses |
| WO2023209068A1 (en) | 2022-04-28 | 2023-11-02 | Carbocalyx Gmbh | Personalized anticancer vaccine comprising glycoengineered tumour cells or tumour cell fragments |
| WO2024062098A1 (en) | 2022-09-23 | 2024-03-28 | Transgene | Recombinant pseudocowpox virus encoding an interleukin-12 |
| CN115927215B (zh) * | 2023-01-18 | 2025-10-17 | 中国医学科学院病原生物学研究所 | 一种定向减毒的痘苗病毒疫苗 |
| CN116656730B (zh) * | 2023-05-25 | 2024-03-19 | 军事科学院军事医学研究院军事兽医研究所 | 一种表达狂犬病病毒g、m蛋白的重组金丝雀痘病毒及其构建方法 |
| WO2026041811A1 (en) | 2024-08-23 | 2026-02-26 | Transgene | Recombinant poxvirus and method for regulating the expression of toxic conditional gene products of said recombinant poxvirus in a producing cell |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4603112A (en) | 1981-12-24 | 1986-07-29 | Health Research, Incorporated | Modified vaccinia virus |
| US7045313B1 (en) | 1982-11-30 | 2006-05-16 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant vaccinia virus containing a chimeric gene having foreign DNA flanked by vaccinia regulatory DNA |
| GB9013750D0 (en) | 1990-06-20 | 1990-08-08 | Pfizer Ltd | Therapeutic agents |
| US5250534A (en) | 1990-06-20 | 1993-10-05 | Pfizer Inc. | Pyrazolopyrimidinone antianginal agents |
| GB9311920D0 (en) | 1993-06-09 | 1993-07-28 | Pfizer Ltd | Therapeutic agents |
| UA68327C2 (en) | 1995-07-04 | 2004-08-16 | Gsf Forschungszentrum Fur Unwe | A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals |
| US5672485A (en) | 1996-08-13 | 1997-09-30 | Regents Of The University Of Minnesota | Immortalized cell lines for virus growth |
| FR2766091A1 (fr) | 1997-07-18 | 1999-01-22 | Transgene Sa | Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee |
| FR2790955B1 (fr) | 1999-03-19 | 2003-01-17 | Assist Publ Hopitaux De Paris | Utilisation d'oligonucleotides stabilises comme principe actif antitumoral |
| UA82466C2 (uk) | 2001-07-18 | 2008-04-25 | Бавариан Нордика А/С | Спосіб посилення ампліфікації хордопоксвірусу |
| NZ533302A (en) | 2001-12-10 | 2005-11-25 | Bavarian Nordic As | Poxvirus containing formulations and process for preparing stable, poxvirus containing compositions containing a disaaccharide and a pharmaceutically acceptable polymer i.e. dextran or polyvinylpyrrolidon (PVP) |
| CA2531565C (en) | 2003-07-22 | 2014-02-11 | Vivalis | Production of poxviruses with adherent or non adherent avian cell lines |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| GB0502661D0 (en) | 2005-02-09 | 2005-03-16 | Stabilitech Ltd | A desiccated product |
| BRPI0618850A2 (pt) | 2005-11-21 | 2011-09-13 | Sanofi Pasteur Ltd | formulações de estabilização para vìrus recombinantes |
| EP1979474B1 (en) | 2006-01-05 | 2010-08-11 | Transgene SA | Avian telomerase reverse transcriptase |
| ES2611975T3 (es) * | 2006-06-20 | 2017-05-11 | Transgene S.A. | Procedimiento para producir poxvirus y composiciones de poxvirus |
| US8420103B2 (en) | 2007-01-30 | 2013-04-16 | Transgene S.A. | Papillomavirus vaccines |
| GB0705245D0 (en) | 2007-03-19 | 2007-04-25 | Stabilitech Ltd | Stable biological products |
| EP1985305A1 (en) | 2007-04-24 | 2008-10-29 | Vivalis | Duck embryonic derived stem cell lines for the production of viral vaccines |
| CA2676149C (en) | 2007-05-14 | 2016-06-21 | Bavarian Nordic A/S | Purification of vaccinia virus- and recombinant vaccinia virus-based vaccines |
| KR20100021603A (ko) | 2007-05-15 | 2010-02-25 | 트랜스진 에스.에이. | 신호전달 펩타이드 |
| ES2618490T3 (es) | 2007-07-03 | 2017-06-21 | Transgene Sa | Estirpes celulares aviares inmortalizadas |
| US8357531B2 (en) | 2007-07-03 | 2013-01-22 | Transgene S.A. | Immortalized avian cell lines |
| AU2008328258B2 (en) | 2007-11-19 | 2013-09-26 | Transgene Sa | Poxviral oncolytic vectors |
| US8778328B2 (en) | 2007-11-19 | 2014-07-15 | Transgene S.A. | Poxviral oncolytic vectors |
| CN102257134B (zh) | 2008-02-12 | 2014-03-05 | 赛诺菲巴斯德有限公司 | 使用离子交换和凝胶过滤色谱进行痘病毒纯化的方法 |
| EP2199400A1 (en) | 2008-12-22 | 2010-06-23 | Emergent Product Development Germany GmbH | Single recombination system and methods of use |
| KR20120026526A (ko) | 2009-05-12 | 2012-03-19 | 트랜스진 에스.에이. | 불멸화 조류 세포주 및 그의 용도 |
| EP2569633B1 (en) * | 2010-05-14 | 2016-02-10 | The General Hospital Corporation | Compositions and methods of identifying tumor specific neoantigens |
| HRP20250981T1 (hr) | 2011-05-24 | 2025-10-24 | BioNTech SE | Individualizirana cjepiva protiv raka |
| WO2013022764A1 (en) | 2011-08-05 | 2013-02-14 | David Kirn | Methods and compositions for production of vaccina virus |
| EP3511425A1 (en) * | 2012-07-12 | 2019-07-17 | Persimmune, Inc. | Personalized cancer vaccines and adoptive immune cell therapies |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| EP3795696B1 (en) * | 2013-03-15 | 2023-04-26 | The Board of Trustees of the Leland Stanford Junior University | Identification and use of circulating nucleic acid tumor markers |
| AU2014251207B2 (en) | 2013-04-07 | 2019-06-13 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for personalized neoplasia vaccines |
| CN106132432A (zh) * | 2013-12-06 | 2016-11-16 | 博德研究所 | 用于瘤形成疫苗的配制品 |
| EP3142690B1 (en) | 2014-05-13 | 2022-02-23 | Bavarian Nordic A/S | Combination therapy for treating cancer with a recombinant poxvirus expressing a tumor antigen and an immune checkpoint molecule antagonist or agonist |
| JP2017515841A (ja) | 2014-05-13 | 2017-06-15 | バヴァリアン・ノルディック・アクティーゼルスカブ | 腫瘍抗原を発現するポックスウイルス及びｔｉｍ−３に対するモノクローナル抗体を用いた癌治療のための併用療法 |
| MX2017014700A (es) | 2015-05-20 | 2018-08-15 | Broad Inst Inc | Neoantigenos compartidos. |
| CN107847611A (zh) | 2015-05-26 | 2018-03-27 | 阿德瓦希斯公司 | 个性化的基于递送载体的免疫疗法及其用途 |
| TW202241500A (zh) * | 2015-06-09 | 2022-11-01 | 美商博德研究所有限公司 | 用於贅瘤疫苗之調配物及其製備方法 |
| EP3313975A4 (en) | 2015-06-24 | 2019-03-13 | Advaxis, Inc. | MANUFACTURING DEVICE AND METHOD FOR PERSONALIZED ADMINISTRATION OF VECTOR-BASED IMMUNOTHERAPY |
| US20170199961A1 (en) * | 2015-12-16 | 2017-07-13 | Gritstone Oncology, Inc. | Neoantigen Identification, Manufacture, and Use |
| WO2017177207A1 (en) * | 2016-04-07 | 2017-10-12 | Bostongene, Llc | Construction and methods of use of a therapeutic cancer vaccine library comprising fusion-specific vaccines |
-
2018
- 2018-06-21 KR KR1020207001211A patent/KR102684237B1/ko active Active
- 2018-06-21 CN CN201880050941.2A patent/CN111065406A/zh active Pending
- 2018-06-21 US US16/625,239 patent/US11969462B2/en active Active
- 2018-06-21 JP JP2019570982A patent/JP7334124B2/ja active Active
- 2018-06-21 CA CA3067405A patent/CA3067405A1/en active Pending
- 2018-06-21 IL IL271558A patent/IL271558B2/en unknown
- 2018-06-21 AU AU2018287159A patent/AU2018287159B2/en active Active
- 2018-06-21 EP EP18731146.9A patent/EP3641803A2/en active Pending
- 2018-06-21 WO PCT/EP2018/066668 patent/WO2018234506A2/en not_active Ceased
- 2018-06-21 KR KR1020247022788A patent/KR20240113607A/ko active Pending
- 2018-06-21 SG SG11201912429RA patent/SG11201912429RA/en unknown
-
2023
- 2023-04-13 US US18/299,858 patent/US20230277639A1/en active Pending
- 2023-06-19 JP JP2023100296A patent/JP2023123609A/ja active Pending
-
2025
- 2025-07-18 JP JP2025121773A patent/JP2025160281A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020530437A5 (enExample) | ||
| JP5873511B2 (ja) | ｍＲＮＡ翻訳エンハンサーエレメントに関する組成物および方法 | |
| Chen et al. | Androgen pathway stimulates microRNA‐216a transcription to suppress the tumor suppressor in lung cancer‐1 gene in early hepatocarcinogenesis | |
| CN102741405B (zh) | 提高基因表达的系统和保持有该系统的载体 | |
| JP2016520320A5 (enExample) | ||
| JP2021501572A5 (enExample) | ||
| CA2983364A1 (en) | Compositions and methods for the treatment of nucleotide repeat expansion disorders | |
| ATE348108T1 (de) | Methode zum nachweis von tumoren | |
| JP2020510426A5 (enExample) | ||
| JPWO2018234506A5 (enExample) | ||
| CA2555013A1 (en) | Carcinoembryonic antigen fusions and uses thereof | |
| JP5926800B2 (ja) | アグロシベ・アエゲリタのレクチンａａｌ−２、及びそのコード遺伝子、その調製方法、及び応用 | |
| US9765305B2 (en) | Mutant vaccinia virus strains, uses thereof and method of producing the same | |
| JPH05502789A (ja) | ムチンヌクレオチド | |
| RU2005137697A (ru) | Синтетический ген, кодирующий человеческий раково-эмбриональный антиген, и его применение | |
| CN102382194A (zh) | 自噬串联荧光探针mTagRFP-mWasabi-LC3及其应用 | |
| RU2020101489A (ru) | Персонализированная вакцина | |
| CN106319043B (zh) | 长链非编码rna linc01420的应用方法 | |
| KR20230019112A (ko) | 암을 포함한 연령-관련 질환을 위한 요법으로서 사용하기 위한 미토콘드리아 유래 펩티드 및 그의 유사체 | |
| JP2023508389A (ja) | 治療用ワクチンのための組換えポックスウイルスを設計する方法 | |
| AU2016335070B2 (en) | Polyepitope constructs for use in immunotherapy | |
| CN103114104A (zh) | 一种抑癌肽基因重组及其抗肿瘤应用 | |
| WO2006089455A1 (en) | Targeting anti-tumour fusion protein containing adenovirus e4orf4 protein | |
| CN111434351B (zh) | TgCPC1在制备抗贫血药物中的应用 | |
| CN101781662A (zh) | 一种人类和哺乳动物细胞游离表达载体 |